2026 Global: Biologics Market-Competitive Review (2032) report
Description
The 2026 Global: Biologics Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biologics market by geography and historical trend. The scope of the report extends to sizing of the biologics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
AbbVie, Johnson & Johnson, Pfizer, Novartis, Roche, Amgen, Merck & Co., AstraZeneca, Eli Lilly, and Novo Nordisk are among the ten major companies dominating the global biologics market due to their extensive biologics portfolios, manufacturing scale, and sustained R&D investment. AbbVie leverages immunology blockbusters and a growing biologics pipeline, supported by acquisitions that extend its biologics and RNA capabilities. Johnson & Johnson combines pharmaceuticals and biologics with significant sales in oncology and immunology, maintaining broad global reach and strong manufacturing capacity. Pfizer’s biologics strength rests on vaccines and monoclonal antibodies, amplified by historic scale and biosimilars activity through past acquisitions that expanded its biologics manufacturing footprint. Novartis maintains a diversified biologics presence spanning oncology and cell and gene therapies, backed by large R&D budgets and strategic biopharma investments. Roche remains a leader in oncology biologics and diagnostics integration, sustaining market leadership through high-impact monoclonal antibodies and targeted biologic therapeutics.
Amgen, Merck & Co., AstraZeneca, Eli Lilly, and Novo Nordisk each contribute distinct strengths that shape biologics competition and growth dynamics. Amgen’s biologics expertise and biosimilar activity position it as a major biologics manufacturer with a pipeline focused on oncology and immunology and steady biosimilar revenues. Merck & Co. benefits from blockbuster biologics in oncology that drive outsized revenue and fund continued biologics R&D and lifecycle management. AstraZeneca’s biologics footprint spans oncology, cardiovascular and rare disease biologics, bolstered by acquisitions that add rare-disease biologics depth and global commercial reach. Eli Lilly has rapidly expanded its biologics and peptide portfolio, gaining market valuation and pipeline momentum in metabolic and endocrine biologic therapies alongside novel modalities. Novo Nordisk dominates metabolic biologics with leading GLP-1 biologic therapies, generating substantial revenues and reinvesting in biologics innovation and manufacturing capacity.
Collectively these ten companies shape the biologics market through large-scale manufacturing, global distribution networks, and aggressive pipeline development across monoclonal antibodies, vaccines, cell and gene therapies, and biosimilars. Their market capitalizations and revenues reflect strong investor confidence tied to biologics performance, recent M&A that secures biologics platforms, and strategic investments in API and biologics manufacturing to mitigate supply-chain and tariff risks. Biosimilars and RNA-based biologics are shifting competitive dynamics, where players such as Pfizer, Amgen, and Sandoz capture substantial biosimilar shares while innovators like AbbVie, Roche, and Novo Nordisk defend franchises with next-generation biologics and lifecycle strategies. Continued growth in biologics is supported by rising global demand for oncology, immunology, and metabolic therapies and by sustained R&D spending from these leading firms that accelerates novel biologic modalities and commercialization capacity.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biologics market by geography and historical trend. The scope of the report extends to sizing of the biologics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
AbbVie, Johnson & Johnson, Pfizer, Novartis, Roche, Amgen, Merck & Co., AstraZeneca, Eli Lilly, and Novo Nordisk are among the ten major companies dominating the global biologics market due to their extensive biologics portfolios, manufacturing scale, and sustained R&D investment. AbbVie leverages immunology blockbusters and a growing biologics pipeline, supported by acquisitions that extend its biologics and RNA capabilities. Johnson & Johnson combines pharmaceuticals and biologics with significant sales in oncology and immunology, maintaining broad global reach and strong manufacturing capacity. Pfizer’s biologics strength rests on vaccines and monoclonal antibodies, amplified by historic scale and biosimilars activity through past acquisitions that expanded its biologics manufacturing footprint. Novartis maintains a diversified biologics presence spanning oncology and cell and gene therapies, backed by large R&D budgets and strategic biopharma investments. Roche remains a leader in oncology biologics and diagnostics integration, sustaining market leadership through high-impact monoclonal antibodies and targeted biologic therapeutics.
Amgen, Merck & Co., AstraZeneca, Eli Lilly, and Novo Nordisk each contribute distinct strengths that shape biologics competition and growth dynamics. Amgen’s biologics expertise and biosimilar activity position it as a major biologics manufacturer with a pipeline focused on oncology and immunology and steady biosimilar revenues. Merck & Co. benefits from blockbuster biologics in oncology that drive outsized revenue and fund continued biologics R&D and lifecycle management. AstraZeneca’s biologics footprint spans oncology, cardiovascular and rare disease biologics, bolstered by acquisitions that add rare-disease biologics depth and global commercial reach. Eli Lilly has rapidly expanded its biologics and peptide portfolio, gaining market valuation and pipeline momentum in metabolic and endocrine biologic therapies alongside novel modalities. Novo Nordisk dominates metabolic biologics with leading GLP-1 biologic therapies, generating substantial revenues and reinvesting in biologics innovation and manufacturing capacity.
Collectively these ten companies shape the biologics market through large-scale manufacturing, global distribution networks, and aggressive pipeline development across monoclonal antibodies, vaccines, cell and gene therapies, and biosimilars. Their market capitalizations and revenues reflect strong investor confidence tied to biologics performance, recent M&A that secures biologics platforms, and strategic investments in API and biologics manufacturing to mitigate supply-chain and tariff risks. Biosimilars and RNA-based biologics are shifting competitive dynamics, where players such as Pfizer, Amgen, and Sandoz capture substantial biosimilar shares while innovators like AbbVie, Roche, and Novo Nordisk defend franchises with next-generation biologics and lifecycle strategies. Continued growth in biologics is supported by rising global demand for oncology, immunology, and metabolic therapies and by sustained R&D spending from these leading firms that accelerates novel biologic modalities and commercialization capacity.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.